Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Urogenital Neoplasms 1Thymoma 1Stomach Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Genital Neoplasms, Female 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1Adrenocortical Carcinoma 1

Interventions

apatinib 3pembrolizumab 2Poly(ADP-ribose) Polymerase Inhibitors 2Hyperthermic Intraperitoneal Chemotherapy 2Bevacizumab 2taxane 1olaparib 1lenvatinib 1fludarabine 1cediranib 1Whole Genome Sequencing 1Valproic Acid 1Tranexamic Acid 1Tai Ji 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Saline Solution 1Radiation 1Qigong 1Propranolol 1Positron Emission Tomography Computed Tomography 1Population Groups 1Platinum 1Paclitaxel 1Neoadjuvant Therapy 1Interleukin-2 1Indocyanine Green 1Immunohistochemistry 1Hydralazine 1Gene Expression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Ovarian Neoplasms × lenvatinib × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡